👤 Shu Wu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
1732
Articles
1210
Name variants
Also published as: Aimin Wu, Alexander T H Wu, Alice Ying-Jung Wu, An Guo Wu, An-Chih Wu, An-Dong Wu, An-Hua Wu, An-Li Wu, An-Xin Wu, Andong Wu, Anguo Wu, Anke Wu, Anna H Wu, Anping Wu, Anshi Wu, Anyi Wu, Anyue Wu, Anzhou Wu, B Wu, Baiyan Wu, Baochuan Wu, Baojian Wu, Baojin Wu, Baoqin Wu, Beier Wu, Beili Wu, Ben J Wu, Bian Wu, Biaoliang Wu, Bifeng Wu, Bill X Wu, Bin Wu, Binbin Wu, Bing Wu, Bing-Bing Wu, Bingjie Wu, Binxin Wu, Biwei Wu, Bo Wu, Boquan Wu, Buling Wu, C Wu, C-H Wu, Cai-Qin Wu, Caihong Wu, Caisheng Wu, Caiwen Wu, Catherine A Wu, Chang-Jiun Wu, Changchen Wu, Changjie Wu, Changjing Wu, Changwei Wu, Changxin Wu, Changyu Wu, Chao Wu, Chao-Liang Wu, Chaoling Wu, Chaowei Wu, Chen Wu, Chen-Lu Wu, Cheng Wu, Cheng-Chun Wu, Cheng-Hsin Wu, Cheng-Hua Wu, Cheng-Jang Wu, Cheng-Jun Wu, Cheng-Yang Wu, Chengbiao Wu, Chengqian Wu, Chengrong Wu, Chengwei Wu, Chengxi Wu, Chengyu Wu, Chenyang Wu, Chew-Wun Wu, Chi-Chung Wu, Chi-Hao Wu, Chi-Jen Wu, Chia-Chang Wu, Chia-Chen Wu, Chia-Ling Wu, Chia-Lung Wu, Chia-Zhen Wu, Chiao-En Wu, Chieh-Jen Wu, Chieh-Lin Stanley Wu, Chien-Sheng Wu, Chien-Ting Wu, Chih-Ching Wu, Chih-Chung Wu, Chih-Hsing Wu, Ching-Yi Wu, Cho-Kai Wu, Chong Wu, Chongming Wu, Choufei Wu, Chris Y Wu, Chuan-Ling Wu, Chuang Wu, Chuanhong Wu, Chun Wu, Chun-Chieh Wu, Chun-Hua Wu, Chunfu Wu, Chung-Yi Wu, Chunru Wu, Chunshuai Wu, Chunyan Wu, Colin Chih-Chien Wu, Colin O Wu, Cong Wu, Congying Wu, Constance Wu, Cuiling Wu, Cuiyan Wu, D I Wu, D P Wu, D Wu, Da-Hua Wu, Dai-Chao Wu, Dan Wu, Dan-Chun Wu, Dandan Wu, Danhong Wu, Danni Wu, Daoyuan Wu, Dapeng Wu, Daqing Wu, Daren Wu, David Wu, Daxian Wu, De Wu, De-Fu Wu, Deguang Wu, Dengying Wu, Depei Wu, Depeng Wu, Deqing Wu, Di Wu, Diana H Wu, Diana Wu, Dianqing Wu, Ding Lan Wu, Dirong Wu, Dishan Wu, Disheng Wu, Do-Bo Wu, Dong Wu, Dong-Bo Wu, Dong-Fang Wu, Dong-Feng Wu, Donglin Wu, Dongmei Wu, Dongping Wu, Dongsheng Wu, Dongyan Wu, Dongzhe Wu, Douglas C Wu, Duojiao Wu, Ed Xuekui Wu, Eugenia Wu, Fan Wu, Fanchang Wu, Fang Wu, Fang-Tzu Wu, Fangge Wu, Fanggeng Wu, Fei Wu, Fei-Fei Wu, Feifei Wu, Fenfang Wu, Feng Wu, Fengming Wu, Fengying Wu, Fong-Li Wu, G Wu, G X Wu, Gaige Wu, Gang Wu, Gaojun Wu, Ge-ru Wu, Gen Sheng Wu, Gen Wu, Geng-ze Wu, Geping Wu, Geting Wu, Geyan Wu, Grace F Wu, Guang-Bo Wu, Guang-Liang Wu, Guang-Long Wu, Guanggeng Wu, Guangjie Wu, Guangming Wu, Guangrun Wu, Guangsen Wu, Guangxi Wu, Guangxian Wu, Guangyan Wu, Guangzhen Wu, Guanhui Wu, Guanming Wu, Guanrong Wu, Guanxian Wu, Guanyi Wu, Guanzhao Wu, Guanzhong Wu, Gui-Qin Wu, Guifen Wu, Guifu Wu, Guihua Wu, Guiping Wu, Guixin Wu, Guizhen Wu, Guo-Chao Wu, Guofeng Wu, Guohao Wu, Guojun Wu, Guoli Wu, Guoping Wu, Guoqing Wu, Guorong Wu, Guoyao Wu, H J Wu, H Wu, Hai-Ping Wu, Hai-Yan Wu, Hai-Yin Wu, Haibin Wu, Haidong Wu, Haihu Wu, Haijiang Wu, Haijing Wu, Hailong Wu, Haiping Wu, Haishan Wu, Haisu Wu, Haiwei Wu, Haixia Wu, Haiyan Wu, Haiying Wu, Haiyun Wu, Han Wu, Han-Jie Wu, Hang Wu, Hanyu Wu, Hao Wu, Hao-Tian Wu, Haoan Wu, Haodi Wu, Haomin Wu, Haoming Wu, Haoxuan Wu, Haoze Wu, He Wu, Hei Man Wu, Hei-Man Wu, Hengyu Wu, Hon-Yen Wu, Hong Wu, Hong-Fu Wu, Hong-Mei Wu, Hongfei Wu, Hongfu Wu, Hongke Wu, Hongliang Wu, Honglin Wu, Hongmei Wu, Hongting Wu, Hongxi Wu, Hongxian Wu, Hongyan Wu, Hongyu Wu, Hsan-Au Wu, Hsi-Chin Wu, Hsien-Ming Wu, Hsing-Chieh Wu, Hsiu-Chuan Wu, Hsueh-Erh Wu, Hua Wu, Hua-Yu Wu, Huan Wu, Huanghui Wu, Huanlin Wu, Huanwen Wu, Huating Wu, Huazhang Wu, Huazhen Wu, Hui Wu, Hui-Chen Wu, Hui-Hui Wu, Hui-Mei Wu, Hui-Xuan Wu, Huijian Wu, Huijuan Wu, Huini Wu, Huisheng Wu, Huiwen Wu, Hung-Tsung Wu, I H Wu, Irene X Y Wu, J W Wu, J Wu, J Y Wu, J-Z Wu, Jamie L Y Wu, Jason H Y Wu, Jason Wu, Jemma X Wu, Jer-Yuan Wu, Jer-Yuarn Wu, Jerry Wu, Ji-Zhou Wu, Jia Wu, Jia-En Wu, Jia-Hui Wu, Jia-Jun Wu, Jia-Qi Wu, Jia-Wei Wu, Jiahang Wu, Jiahao Wu, Jiahui Wu, Jiajin Wu, Jiajing Wu, Jiake Wu, Jiamei Wu, Jian Hui Wu, Jian Wu, Jian-Lin Wu, Jian-Qiu Wu, Jian-Yi Wu, Jiang Wu, Jiang-Bo Wu, Jiang-Nan Wu, Jiangdong Wu, Jianguang Wu, Jiangyue Wu, Jianhui Wu, Jianing Wu, Jianjin Wu, Jianjun Wu, Jianli Wu, Jianliang Wu, Jianmin Wu, Jianming Wu, Jianping Wu, Jianqiang Wu, Jianrong Wu, Jianwu Wu, Jianxin Wu, Jianxiong Wu, Jianyi Wu, Jianying Wu, Jianzhang Wu, Jianzhi Wu, Jianzhong Wu, Jiao Wu, Jiapei Wu, Jiaqi Wu, Jiarui Wu, Jiawei Wu, Jiaxi Wu, Jiaxuan Wu, Jiayi Wu, Jiayu Wu, Jiayuan Wu, Jie Wu, JieQian Wu, Jiexi Wu, Jihui Wu, Jin Wu, Jin'en Wu, Jin-Shang Wu, Jin-Zhen Wu, Jin-hua Wu, Jincheng Wu, Jinfeng Wu, Jing Wu, Jing-Fang Wu, Jing-Wen Wu, Jinghong Wu, Jingjing Wu, Jingtao Wu, Jingwan Wu, Jingyi Wu, Jingyue Wu, Jingyun Wu, Jinhua Wu, Jinhui Wu, Jinjie Wu, Jinjun Wu, Jinmei Wu, Jinqiao Wu, Jinyu Wu, Jinze Wu, Jiong Wu, Jiu-Lin Wu, Joseph C Wu, Joshua L Wu, Ju Wu, Juan Wu, Juanjuan Wu, Juanli Wu, Jugang Wu, Julian Wu, Jun Wu, Jundong Wu, Junduo Wu, June K Wu, June-Hsieh Wu, Junfang Wu, Junfei Wu, Junfeng Wu, Junhua Wu, Junjie Wu, Junjing Wu, Junlong Wu, Junqi Wu, Junqing Wu, Junshu Wu, Junyi Wu, Junyong Wu, Junzheng Wu, Junzhu Wu, Justin C Y Wu, Justin Che-Yuen Wu, K D Wu, K S Wu, Kai-Hong Wu, Kai-Yue Wu, Kailang Wu, Kaili Wu, Kan Wu, Kay L H Wu, Ke Wu, Kebang Wu, Keija Wu, Kejia Wu, Kerui Wu, Kevin Zl Wu, Kuan-Li Wu, Kuen-Phon Wu, Kui Wu, Kuixian Wu, Kun Wu, Kun-Rong Wu, Kunfang Wu, Kunling Wu, Kunsheng Wu, L Wu, L-F Wu, Lai Man Natalie Wu, Lan Wu, Lanlan Wu, Lanxiang Wu, Lecheng Wu, Lei Wu, Leilei Wu, Lesley Wu, Leslie Wu, Li Wu, Li-Hsien Wu, Li-Jun Wu, Li-Ling Wu, Li-Na Wu, Li-Peng Wu, Liang Wu, Liang-Huan Wu, Liangyan Wu, Lianqian Wu, Lichao Wu, Lidi Wu, Lifang Wu, Lifeng Wu, Lihong Wu, Lijie Wu, Lijuan Wu, Lijun Wu, Lili Wu, Limei Wu, Limeng Wu, Lin Wu, Lin-Han Wu, Ling Wu, Ling-Fei Wu, Ling-Ying Wu, Ling-qian Wu, Lingling Wu, Lingqian Wu, Lingxi Wu, Lingxiang Wu, Lingyan Wu, Lingyun Wu, Lingzhi Wu, Linhong Wu, Linmei Wu, Lintao Wu, Linxiang Wu, Linyu Wu, Linzhen Wu, Linzhi Wu, Lipeng Wu, Liping Wu, Liqiang Wu, Liqun Wu, Liren Wu, Lisha Wu, Liting Wu, Litong Wu, Liufeng Wu, Liuting Wu, Liuxin Wu, Liuying Wu, Lixing Wu, Liyan Wu, Liyang Wu, Lizhen Wu, Lizi Wu, Long-Jun Wu, Longting Wu, Lorna Wu, Lulu Wu, Lun Wu, Lun-Gang Wu, Luyan Wu, M Wu, Ma Wu, Man Wu, Man-Jing Wu, Maoqing Wu, Mark N Wu, Matthew A Wu, Maureen Wu, Mei Wu, Mei-Hwan Wu, Mei-Na Wu, Meili Wu, Meina Wu, Meini Wu, Meiqi Wu, Meiqin Wu, Meng Wu, Meng-Chao Wu, Meng-Han Wu, Meng-Hsun Wu, Meng-Ling Wu, Meng-Na Wu, Mengbo Wu, Mengchao Wu, Mengjuan Wu, Mengjun Wu, Mengna Wu, Mengqiu Wu, Mengxue Wu, Mengying Wu, Mengyuan Wu, Mian Wu, Michael C Wu, Min Wu, Min-Jiao Wu, Ming J Wu, Ming Wu, Ming-Der Wu, Ming-Jiuan Wu, Ming-Shiang Wu, Ming-Sian Wu, Ming-Tao Wu, Ming-Yue Wu, Mingfu Wu, Minghua Wu, Mingjie Wu, Mingjun Wu, Mingming Wu, Mingxing Wu, Mingxuan Wu, Minna Wu, Minqing Wu, Minyao Wu, Moxin Wu, Muzhou Wu, N Wu, Na Wu, Na-Qiong Wu, Nan Wu, Nana Wu, Naqiong Wu, Ning Wu, Nini Wu, Niting Wu, P L Wu, Panyun Wu, Paul W Wu, Pei Wu, Pei-Ei Wu, Pei-Ting Wu, Pei-Wen Wu, Pei-Yu Wu, Peih-Shan Wu, Peiyao Wu, Peiyi Wu, Peng Wu, Peng-Fei Wu, Pengfei Wu, Pengjie Wu, Pengning Wu, Pensee Wu, Pin Wu, Ping Wu, Ping-Hsun Wu, Pinglian Wu, Pingxian Wu, Po-Chang Wu, Qi Wu, Qi-Biao Wu, Qi-Fang Wu, Qi-Jun Wu, Qi-Nian Wu, Qi-Yong Wu, Qi-Zhu Wu, Qian Wu, Qian-Yan Wu, Qiang Wu, Qianhu Wu, Qianqian Wu, Qianwen Wu, Qiao Wu, Qiaowei Wu, Qibiao Wu, Qibing Wu, Qihan Wu, Qijing Wu, Qin Wu, Qinan Wu, Qinfeng Wu, Qing Wu, Qing-Qian Wu, Qing-Wu Wu, Qinghua Wu, Qinglan Wu, Qinglin Wu, Qingping Wu, Qingshi Wu, Qinyi Wu, Qiong Wu, Qiqing Wu, Qitian Wu, Qiu Wu, Qiu-Li Wu, Qiuchen Wu, Qiuhong Wu, Qiuji Wu, Qiulian Wu, Qiuliang Wu, Qiuxia Wu, Qiuya Wu, Quanhui Wu, Qunzheng Wu, R M Wu, R Ryanne Wu, R Wu, R-J Wu, Ran Wu, Ray-Chin Wu, Re-Wen Wu, Ren Wu, Ren-Chin Wu, Renhai Wu, Renlv Wu, Renrong Wu, Riping Wu, Rong Wu, Ronghua Wu, Rongjie Wu, Rongling Wu, Rongrong Wu, Ru-Zi Wu, Rui Wu, Ruihong Wu, Ruize Wu, Run Wu, Runda Wu, Runpei Wu, Ruohao Wu, Ruolan Wu, Ruonan Wu, Ruying Wu, S F Wu, S J Wu, S L Wu, S M Wu, S Wu, S-F Wu, Sai Wu, Samuel M Wu, San-pin Wu, Sarah Wu, Sean M Wu, Selena Meiyun Wu, Selwin K Wu, Semon Wu, Sen-Chao Wu, Senquan Wu, Sensen Wu, Shao-Guo Wu, Shao-Ming Wu, Shaofei Wu, Shaohuan Wu, Shaojun Wu, Shaoping Wu, Shaoxuan Wu, Shaoyu Wu, Shaoze Wu, Sheng-Li Wu, Shengde Wu, Shengming Wu, Shengnan Wu, Shengru Wu, Shengxi Wu, Shenhao Wu, Shenyue Wu, Shi-Xin Wu, Shibo Wu, Shih-Ying Wu, Shihao Wu, Shin-Long Wu, Shinan Wu, Shiqi Wu, Shiwen Wu, Shixin Wu, Shiya Wu, Shiyang Wu, Shuai Wu, Shuang Wu, Shufang Wu, Shugeng Wu, Shuihua Wu, Shuisheng Wu, Shujuan Wu, Shunan Wu, Shuo Wu, Shusheng Wu, Shuting Wu, Shuyan Wu, Shuyi Wu, Shuying Wu, Shwu-Yuan Wu, Shyh-Jong Wu, Si-Jia Wu, Sichen Wu, Sihan Wu, Sihui Wu, Sijie Wu, Sijun Wu, Siming Wu, Siqi Wu, Siyi Wu, Siying Wu, Siyu Wu, Song Wu, Songfen Wu, Su Wu, Su-Hui Wu, Suhua Wu, Sunyi Wu, Szu-Hsien Wu, T Wu, Tangchun Wu, Tao Wu, Teng Wu, Terence Wu, Thomas D Wu, Tian Wu, Tiange Wu, Tianhao Wu, Tianqi Wu, Tiantian Wu, Tianwen Wu, Tianzhi Wu, Ting-Feng Wu, Ting-Ting Wu, Tingchun Wu, Tingqin Wu, Tingting Wu, Tong Wu, Tracy Wu, Tsai-Kun Wu, Tsung-Jui Wu, Tsung-Teh Wu, Tung-Ho Wu, Tzu-Chun Wu, V C Wu, W J Wu, W Wu, Wan-Fu Wu, Wanxia Wu, Wei Wu, Wei-Chi Wu, Wei-Ping Wu, Wei-Xun Wu, Wei-Yin Wu, Weibin Wu, Weida Wu, Weidong Wu, Weihua Wu, Weijie Wu, Weijun Wu, Weiwei Wu, Weizhen Wu, Wen Wu, Wen-Chieh Wu, Wen-Hui Wu, Wen-Jeng Wu, Wen-Juan Wu, Wen-Ling Wu, Wen-Qiang Wu, Wen-Sheng Wu, Wen-Shu Wu, Wenda Wu, Wendy Wu, Wenhui Wu, Wenjie Wu, Wenjing Wu, Wenjuan Wu, Wenjun Wu, Wenlin Wu, Wenqi Wu, Wenqian Wu, Wenqiang Wu, Wenwen Wu, Wenxian Wu, Wenxue Wu, Wenyi Wu, Wenyong Wu, Wenyu Wu, Wenze Wu, William K K Wu, William Ka Kei Wu, Wu-Tian Wu, Wudelehu Wu, Wujun Wu, Wutain Wu, Wutian Wu, Xi Wu, Xi-Chen Wu, Xi-Ze Wu, Xia Wu, Xiahui Wu, Xian-Run Wu, Xianan Wu, Xianfeng Wu, Xiangping Wu, Xiangsheng Wu, Xiangwei Wu, Xiangxin Wu, Xianpei Wu, Xiao Wu, Xiao-Cheng Wu, Xiao-Hui Wu, Xiao-Jin Wu, Xiao-Jun Wu, Xiao-Yan Wu, Xiao-Yang Wu, Xiao-Ye Wu, Xiao-Yuan Wu, Xiaobin Wu, Xiaobing Wu, Xiaodi Wu, Xiaodong Wu, Xiaofan Wu, Xiaofeng Wu, Xiaofu Wu, Xiaohong Wu, Xiaohui Wu, Xiaojiang Wu, Xiaojie Wu, Xiaojin Wu, Xiaojing Wu, Xiaojun Wu, Xiaokang Wu, Xiaoke Wu, Xiaolang Wu, Xiaoli Wu, Xiaoliang Wu, Xiaolin Wu, Xiaoling Wu, Xiaolong Wu, Xiaoman Wu, Xiaomei Wu, Xiaomeng Wu, Xiaomin Wu, Xiaoming Wu, Xiaoping Wu, Xiaoqian Wu, Xiaoqing Wu, Xiaoqiong Wu, Xiaorong Wu, Xiaoting Wu, Xiaotong Wu, Xiaoxing Wu, Xiaoyang Wu, Xiaoying Wu, Xiaoyong Wu, Xiaoyun Wu, Xiayin Wu, Xiexing Wu, Xifeng Wu, Xihai Wu, Xilin Wu, Xilong Wu, Ximei Wu, Xin Wu, Xin-Xi Wu, Xinchun Wu, Xing Wu, Xing-De Wu, Xing-Ping Wu, Xingdong Wu, Xinghua Wu, Xingjie Wu, Xinglong Wu, Xingwei Wu, Xinhe Wu, Xinjing Wu, Xinlei Wu, Xinmiao Wu, Xinran Wu, Xinrui Wu, Xinyan Wu, Xinyang Wu, Xinyi Wu, Xinyin Wu, Xiping Wu, Xiru Wu, Xiu-Zhi Wu, Xiuhua Wu, Xiushan Wu, Xiwei Wu, Xu Wu, Xuan Wu, Xuanqin Wu, Xuanshuang Wu, Xudong Wu, Xue Wu, Xue-Mei Wu, Xue-Yan Wu, Xuefen Wu, Xuefeng Wu, Xueji Wu, Xuekun Wu, Xueling Wu, Xuemei Wu, Xueqian Wu, Xueqing Wu, Xueyan Wu, Xueyao Wu, Xueying Wu, Xueyuan Wu, Xuhan Wu, Xunwei Wu, Xuxian Wu, Y H Wu, Y Q Wu, Y Wu, Y Y Wu, Y-W Wu, Ya Wu, Yadi Wu, Yafei Wu, Yajie Wu, Yalan Wu, Yali Wu, Yan Wu, Yan Yan Wu, Yan-Hua Wu, Yan-Jun Wu, Yan-ling Wu, Yanan Wu, Yanchuan Wu, Yanchun Wu, Yandi Wu, Yang Wu, Yangfeng Wu, Yangna Wu, Yangyu Wu, Yanhong Wu, Yanhua Wu, Yanhui Wu, Yanjing Wu, Yanli Wu, Yanqiong Wu, Yanran Wu, Yansheng Wu, Yanting Wu, Yanxiang Wu, Yanyan Wu, Yanzhi Wu, Yao Wu, Yaohong Wu, Yaohua Wu, Yaojiong Wu, Yaoxing Wu, Yaping Wu, Yaqin Wu, Yaru Wu, Yawei Wu, Yawen Wu, Ye Wu, Yen-Wen Wu, Yetong Wu, Yexiang Wu, Yi Wu, Yi-Cheng Wu, Yi-Fang Wu, Yi-Hua Wu, Yi-Long Wu, Yi-Mi Wu, Yi-Ming Wu, Yi-No Wu, Yi-Syuan Wu, Yi-Xia Wu, Yi-Ying Wu, Yibo Wu, Yichen Wu, Yicheng Wu, Yifan Wu, Yifeng Wu, Yih-Jer Wu, Yih-Ru Wu, Yihan Wu, Yihang Wu, Yihe Wu, Yihua Wu, Yihui Wu, Yijian Wu, Yili Wu, Yillin Wu, Yilong Wu, Yin Wu, Yinan Wu, Ying Wu, Ying-Ting Wu, Ying-Ying Wu, Yingbiao Wu, Yinghao Wu, Yingning Wu, Yingxia Wu, Yingying Wu, Yingzhi Wu, Yipeng Wu, Yiping Wu, Yiqun Wu, Yiran Wu, Yiting Wu, Yiwen Wu, Yixia Wu, Yixuan Wu, Yiyang Wu, Yiyi Wu, Yizhou Wu, Yong Wu, Yong-Hao Wu, Yong-Hong Wu, Yongfa Wu, Yongfei Wu, Yonghui Wu, Yongjiang Wu, Yongmei Wu, Yongqi Wu, Yongqun Wu, You Wu, Yu Wu, Yu'e Wu, Yu-Chih Wu, Yu-E Wu, Yu-Hsuan Wu, Yu-Ke Wu, Yu-Ling Wu, Yu-Ting Wu, Yu-Yuan Wu, Yuan Kai Wu, Yuan Wu, Yuan-de Wu, Yuanbing Wu, Yuanhao Wu, Yuanming Wu, Yuanshun Wu, Yuanyuan Wu, Yuanzhao Wu, Yucan Wu, Yuchen Wu, Yudan Wu, Yue Wu, Yueheng Wu, Yueling Wu, Yueming Wu, Yuen-Jung Wu, Yuesheng Wu, Yuetong Wu, Yuexiu Wu, Yuguang Philip Wu, Yuh-Lin Wu, Yuhong Wu, Yujie Wu, Yujuan Wu, Yukang Wu, Yulian Wu, Yuliang Wu, Yulin Wu, Yumei Wu, Yumin Wu, Yuming Wu, Yun Wu, Yun-Wen Wu, Yuna Wu, Yung-Fu Wu, Yunhua Wu, Yunpeng Wu, Yupeng Wu, Yuqin Wu, Yurong Wu, Yushun Wu, Yuting Wu, Yutong Wu, Yuwei Wu, Yuxian Wu, Yuxiang Wu, Yuxin Wu, Yuyi Wu, Yuyu Wu, Z Wu, Zaihao Wu, Ze Wu, Zelai Wu, Zeng-An Wu, Zhangjie Wu, Zhao-Bo Wu, Zhao-Yang Wu, Zhaofei Wu, Zhaoxia Wu, Zhaoyang Wu, Zhaoyi Wu, Zhaoyuan Wu, Zhe Wu, Zheming Wu, Zhen Wu, Zhen-Qi Wu, Zhen-Yang Wu, Zhenfang Wu, Zhenfeng Wu, Zheng Wu, Zhengcan Wu, Zhengfeng Wu, Zhengliang L Wu, Zhengsheng Wu, Zhenguo Wu, Zhengyu Wu, Zhengzhi Wu, Zhenling Wu, Zhenlong Wu, Zhentian Wu, Zhenyan Wu, Zhenyong Wu, Zhenzhen Wu, Zhenzhou Wu, Zhi-Hong Wu, Zhi-Wei Wu, Zhi-Yong Wu, Zhibing Wu, Zhichong Wu, Zhidan Wu, Zhihao Wu, Zhikang Wu, Zhimin Wu, Zhipeng Wu, Zhiping Wu, Zhiqiang Wu, Zhixiang Wu, Zhiye Wu, Zhong Wu, Zhong-Jun Wu, Zhong-Yan Wu, Zhongchan Wu, Zhonghui Wu, Zhongjun Wu, Zhongluan Wu, Zhongqiu Wu, Zhongren Wu, Zhongwei Wu, Zhongyang Wu, Zhou Wu, Zhou-Ming Wu, Zhourui Wu, Zhuanbin Wu, Zhuokai Wu, Zhuoze Wu, Zhuzhu Wu, Zijun Wu, Ziliang Wu, Zilong Wu, Zimu Wu, Zixiang Wu, Zixuan Wu, Zoe Wu, Zong-Jia Wu, Zongfu Wu, Zongheng Wu, Zujun Wu, Zuping Wu
articles
Qi-Nian Wu, Yi-Fu Liao, Yun-Xin Lu +9 more · 2025 · Cancer letters · Elsevier · added 2026-04-24
no PDF DOI: 10.1016/j.canlet.2025.217983
DUSP6
Siqi Tang, Wenshu Luo, Cheng Cheng +3 more · 2025 · Biochemistry and biophysics reports · Elsevier · added 2026-04-24
Brain-derived neurotrophic factor (BDNF) protects neurons from degeneration, making it a promising therapeutic target for Alzheimer's disease (AD). However, the genetic regulation resulting from BDNF Show more
Brain-derived neurotrophic factor (BDNF) protects neurons from degeneration, making it a promising therapeutic target for Alzheimer's disease (AD). However, the genetic regulation resulting from BDNF overexpression in the brain remains to be further illustrated. Using APP/PS1 and rTg4510 mouse models, we analyzed hippocampal transcriptomes after intrahippocampal AAVT42- Show less
📄 PDF DOI: 10.1016/j.bbrep.2025.102089
DUSP6
Nieke Zhang, Zhicong Huang, Yi Xia +14 more · 2025 · Journal of nanobiotechnology · BioMed Central · added 2026-04-24
Remote ischemic preconditioning (rIPC) has been reported to protect against kidney ischemia-reperfusion injury (IRI) through the delivery of extracellular vesicles (EVs). Among these, apoptosis-induce Show more
Remote ischemic preconditioning (rIPC) has been reported to protect against kidney ischemia-reperfusion injury (IRI) through the delivery of extracellular vesicles (EVs). Among these, apoptosis-induced compensatory proliferation signaling-related vesicles (ACPSVs) can transmit proliferation signals to surrounding cells. However, the underlying mechanisms remain unclear. This study aimed to investigate the role of ACPSVs in renal IRI following rIPC and to elucidate the associated mechanisms. We demonstrated that rIPC plasma or ACPSVs alleviated renal damage and inflammation, with the protective effects abolished upon the removal of ACPSVs from the plasma. EVs isolated via differential centrifugation exhibited defining characteristics of ACPSVs. Co-culture experiments revealed that ACPSVs reduced apoptosis and enhanced the viability of HK-2 cells under hypoxia/reoxygenation (H/R) conditions. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses highlighted the critical role of macrophage migration inhibitory factor (MIF) protein in ACPSVs. Using CRISPR/Cas9 technology, we generated MIF-knockout HeLa cells to induce the production of MIF-deficient ACPSVs. The protective effects of ACPSVs were significantly attenuated when MIF was knocked out. Transcriptome sequencing and chromatin immunoprecipitation (ChIP) assays revealed that MIF suppresses dual-specificity phosphatase 6 (DUSP6) expression by promoting H3K9 trimethylation (H3K9me3) in the DUSP6 promoter region, thereby activating the JNK signaling pathway. In rescue experiments, treatment with the DUSP6 inhibitor BCI effectively restored the protective function of MIF-deficient ACPSVs. This study underscores the protective role of ACPSVs derived from rIPC-treated rats and serum-starved cells against renal IRI through the MIF/DUSP6/JNK signaling axis, offering a potential clinical therapeutic strategy for acute kidney injury induced by IRI. [Image: see text] The online version contains supplementary material available at 10.1186/s12951-025-03505-9. Show less
📄 PDF DOI: 10.1186/s12951-025-03505-9
DUSP6
Lishang Liao, Qiongdan Hu, Yong Zhang +5 more · 2025 · International immunopharmacology · Elsevier · added 2026-04-24
The aim of this review is to systematically explore the critical role of dual-specific phosphatases (DUSPs) in CKD-associated cognitive impairment and their therapeutic potential. Chronic kidney disea Show more
The aim of this review is to systematically explore the critical role of dual-specific phosphatases (DUSPs) in CKD-associated cognitive impairment and their therapeutic potential. Chronic kidney disease (CKD) is a global health burden, and the cognitive impairment it induces seriously affects patients' quality of life. Studies have shown that DUSPs are involved in pathological processes such as inflammation, oxidative stress, fibrosis, and neuronal apoptosis through the regulation of signaling pathways such as MAPK, which in turn affects the cognitive function of CKD patients. Specifically, downregulation of DUSP1 and DUSP6 expression in brain tissues of CKD patients is associated with cognitive impairment, whereas upregulation of DUSP8 and DUSP16 exacerbates cognitive deficits by promoting neuroinflammation. In addition, uremic toxins (e.g., indolephenol sulfate) can further deteriorate cognitive function by altering the activity of DUSPs and interfering with central nervous system signaling. Although there are currently no clinical drugs targeting DUSPs, small molecule inhibitors, gene modulation techniques, and natural compounds have demonstrated the potential to improve cognitive function by modulating DUSPs. Future studies need to focus on optimizing the specificity and selectivity of DUSPs inhibitors and conducting rigorous clinical validation. In-depth elucidation of the mechanism of action of DUSPs in the renal-brain axis will provide an important theoretical basis for the development of novel intervention strategies for CKD-associated cognitive impairment. Show less
no PDF DOI: 10.1016/j.intimp.2025.114883
DUSP6
Dongmei Zhang, Meiqi Zhao, Ping Jiang +13 more · 2025 · Journal of translational medicine · BioMed Central · added 2026-04-24
Cervical cancer remains one of the leading causes of cancer-related deaths among women globally, and there is still a need to research molecular targets that can be used for prognosis assessment and p Show more
Cervical cancer remains one of the leading causes of cancer-related deaths among women globally, and there is still a need to research molecular targets that can be used for prognosis assessment and personalized molecular therapies. Here, we investigate the role of potential molecular target ribosomal L22-like 1 (RPL22L1) on cervical cancer, identify its potential mechanisms, and explore its related applications in prognosis and molecular therapies. Multiple cervical cancer cohorts online, tissue microarrays and clinical tissue specimens were analyzed for the association between RPL22L1 expression and patient outcomes. Functional and molecular biology studies of cell and mice models were used to clarify the effects and potential mechanisms of RPL22L1 on cervical cancer. RPL22L1 is highly expressed in both cervical adenocarcinoma and squamous cell carcinoma, and its expression is significantly associated with histology grade, clinical stage, recurrence, vascular space involvement, tumor sizes and poor prognosis. In vitro and in vivo experiment revealed that RPL22L1 overexpression significantly promoted cervical cancer cell proliferation, migration, invasion, tumorigenicity and Sorafenib resistance, which were attenuated by RPL22L1 knockdown. Mechanistically, RPL22L1 competitively binds to ERK phosphatase DUSP6, leading to excessive activation of ERK. The combined application of ERK inhibitors can effectively inhibit RPL22L1 overexpressing cervical cancer cells both in vivo and in vitro. RPL22L1 promotes malignant biological behavior of cervical cancer cells by competitively binding with DUSP6, thereby activating the ERK pathway. The combined use of Sorafenib and an ERK inhibitor is a potentially effective molecular targeted therapy for RPL22L1-high cervical cancer. Show less
📄 PDF DOI: 10.1186/s12967-025-06249-0
DUSP6
Qiankun Bai, Jianan Liu, Jie Zhao +4 more · 2025 · Frontiers in cellular and infection microbiology · Frontiers · added 2026-04-24
Here, we identified a type of hypothetical T7SS effector in This alternative strategy facilitates effectors' delivery, even for fragmented substrates, highlighting its importance in ensuring the funct Show more
Here, we identified a type of hypothetical T7SS effector in This alternative strategy facilitates effectors' delivery, even for fragmented substrates, highlighting its importance in ensuring the functionality of T7SS. Show less
📄 PDF DOI: 10.3389/fcimb.2025.1685307
EXT1
Xueqian Wang, Shengzhuang Guan, Yiqing Gao +13 more · 2025 · Frontiers in endocrinology · Frontiers · added 2026-04-24
Brachydactyly type E (BDE) is characterized by variable shortening of metacarpals or metatarsals, often involving phalanges. It may occur as an isolated anomaly or as part of congenital syndromes. Wit Show more
Brachydactyly type E (BDE) is characterized by variable shortening of metacarpals or metatarsals, often involving phalanges. It may occur as an isolated anomaly or as part of congenital syndromes. With advancements in molecular diagnostic technologies, how genetic testing enhances the precise diagnosis of BDE remains unclear. Our aims were to establish an algorithm for molecular genetic diagnostics in Chinese children with BDE and to explore the phenotype-genotype correlations of Chinese patients with BDE. We reviewed left-hand wrist X-rays from children visiting Children's Hospital of Soochow University (Jun 2021-Dec 2023). From 60,650 films, 135 BDE cases were identified, and their comprehensive phenotypes were collected. Whole-exome sequencing (WES) with copy number variation (CNV) analysis was performed on 60 patients and their parents. Sanger sequencing was used to validate single nucleotide variants (SNV) and indels. Causative variants were found in 19 patients. SNVs and indels affecting 10 genes were identified in 15 patients, and CNVs in four. Through comprehensive evaluation of genotype-phenotype correlations, we propose a diagnostic algorithm for precise molecular diagnosis in Chinese children with BDE. Show less
📄 PDF DOI: 10.3389/fendo.2025.1571136
EXT1
Jingxuan Lian, Xiaohui Duan, Wenjie Chen +6 more · 2025 · Cell death discovery · Nature · added 2026-04-24
Gastrointestinal (GI) cancers exhibit aberrant lipid metabolism, yet the causal mechanisms remain elusive. Here, we integrated Mendelian randomization (MR) and multi-omics data to dissect metabolic dr Show more
Gastrointestinal (GI) cancers exhibit aberrant lipid metabolism, yet the causal mechanisms remain elusive. Here, we integrated Mendelian randomization (MR) and multi-omics data to dissect metabolic drivers of 20 GI diseases. Focusing on colorectal (CC) and esophageal cancer (EC), we identified five metabolites (e.g., 1,2-di-palmitoyl-sn-glycero-3-phosphocholine) and arachidonic acid ethyl ester as causal drivers. Summary-data-based MR and colocalization analysis (PP.H4 > 0.75) revealed FADS1 as a master regulator of these metabolites, with genetic variants exhibiting tissue-specific lipidomic effects. Functional validation using FADS1-knockout cell lines and mouse models demonstrated that FADS1 inhibition suppresses tumor cell proliferation, migration, and invasion while promoting apoptosis. In vivo, FADS1 deletion reduced chemically induced CC/EC tumor burden by 62-75%, accompanied by decreased Ki-67/MMP-9 expression and inflammatory infiltration. Mechanistically, FADS1 ablation disrupted lipid metabolism (reduced linoleic acid and arachidonic acid) and attenuated PI3K/AKT and MAPK signaling. Multi-omics integration further corroborated FADS1-mediated epigenetic regulation (e.g., mQTL-driven DNA methylation). This study establishes FADS1 as a pivotal orchestrator of GI carcinogenesis via metabolic reprogramming and signaling dysregulation, offering a compelling therapeutic target for precision oncology in CC and EC. Regulatory mechanisms of FADS1 in CC and EC. Show less
📄 PDF DOI: 10.1038/s41420-025-02768-3
FADS1
Jian Xu, Yuhan Wang, Weiqi Mao +9 more · 2025 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Acute respiratory distress syndrome (ARDS) is a severe clinical condition characterized by widespread inflammation and fluid accumulation in the lungs. Endothelial cell (EC) metabolic changes in acute Show more
Acute respiratory distress syndrome (ARDS) is a severe clinical condition characterized by widespread inflammation and fluid accumulation in the lungs. Endothelial cell (EC) metabolic changes in acute lung injury (ALI) and their relationship to injury remain unclear. Transcriptomic and lipidomic analyses revealed downregulation of PUFA synthesis pathways, particularly omega-3 PUFAs, in pulmonary ECs during LPS-induced ALI. Activation of the PUFA metabolic pathway, through FADS1/2 overexpression or omega-3 fatty acid supplementation, protected ECs from ferroptosis and restored barrier function. In vivo, pulmonary EC-specific overexpression of FADS1/2 contributed to the alleviation of ALI. Overexpression of whole lung FADS1/2, combined with alpha-linolenic acid (ALA) supplementation, also significantly mitigated ALI. PARK7 is identified as an endogenous regulator of FADS1/2, acting through the BMP-BMPR-SMAD1/5/9 signaling. Driven by histone H3K14 lactylation, which is also promoted by the downregulation of FADS1/2, PARK7 upregulation restored FADS1/2 expression and counteracted ferroptosis, thereby forming a protective feedback loop. This study elucidates a novel regulatory axis involving the two major metabolic changes-downregulation of PUFA synthesis and upregulation of histone lactylation-in ALI pathogenesis, which are interconnected through the PARK7-BMP signaling pathway. Targeting this axis offers potential therapeutic strategies for mitigating endothelial dysfunction and ferroptosis in ARDS/ALI. Show less
📄 PDF DOI: 10.1002/advs.202508725
FADS1
Haotian Chen, Zhengye Liu, Hanze Du +7 more · 2025 · BMJ open gastroenterology · added 2026-04-24
Gallstone disease (GD) is a common gastrointestinal disorder with a significant genetic component. Despite known risk factors, the genetic basis of GD remains incompletely understood. We aimed to iden Show more
Gallstone disease (GD) is a common gastrointestinal disorder with a significant genetic component. Despite known risk factors, the genetic basis of GD remains incompletely understood. We aimed to identify novel genetic loci associated with GD, explore their clinical implications and investigate their therapeutic potential. We conducted a genome-wide association study from the UK Biobank followed by a meta-analysis, integrating summary statistics from the FinnGen R11, with further replication from Biobank Japan. Using systematic bioinformatic approaches, we performed gene prioritisation, colocalisation analysis, transcriptome-wide association study, Mendelian randomisations, cross-trait genetic correlations, phenome-wide association study, clinical investigations and gene-environment interactions by leveraging data from the FinnGen, Genotype-Tissue Expression project and Liver Cell Atlas single-cell transcriptomics data set. Our study highlighted novel susceptibility loci near candidate genes (ie, This study provides new insights into the genetic basis of GD and highlights the role of hepatocytes in GD pathogenesis. These findings have implications for the personalised prevention strategies and new therapeutic interventions in individuals predisposed to GD. Show less
📄 PDF DOI: 10.1136/bmjgast-2025-001976
FADS1
Xi-Xi Li, Pei Shi, Fei-Fei Wu +1 more · 2025 · Discover oncology · Springer · added 2026-04-24
With the sharp increase in the incidence of papillary thyroid carcinoma (PTC), the disease-specific survival rate has not improved significantly. Cholesterol metabolism plays a crucial role in tumor p Show more
With the sharp increase in the incidence of papillary thyroid carcinoma (PTC), the disease-specific survival rate has not improved significantly. Cholesterol metabolism plays a crucial role in tumor proliferation, regulation of tumor immune escape, and tumor drug resistance. However, there are few studies on the role of cholesterol metabolism in the occurrence and development of thyroid cancer (THCA). This study aimed to investigate the predictive value of cholesterol metabolism-related genes (CMRGs) in THCA and the relationship between immune invasion and drug sensitivity. Cholesterol metabolism-related genes we identified from the molecular signatures database, and univariate Cox regression and least absolute shrinkage and selection operator(LASSO) were used to construct a predictive model of cholesterol metabolism-related genes based on the TCGA-THCA dataset. The TCGA dataset was randomly divided into a training group and a validation group to verify the model's predictive value and independent prognostic effect. We then constructed a nomogram and performed enrichment analysis, immune cell infiltration, and drug sensitivity analysis. Finally, TCGA-THCA and GSE33630 datasets were used to detect the expression of signature genes, which was further verified by the HPA database. Six CMRGs (FADS1, NPC2, HSD17B7, ACSL4, APOE, HMGCS2) we identified by univariate Cox and LASSO regression to construct a prognostic model for 155 genes related to cholesterol metabolism. Their prognostic value was confirmed in the validation set, and a highly accurate nomogram was constructed combined with clinical features. We found that the mortality rate of high-risk patients increased by 11.41 times, and the infiltration of immune cells in the high-risk group was significantly reduced. Moreover, through drug sensitivity analysis, we obtained sensitive drugs for different risk groups. The GSE33630 dataset verified the expression of six CMRGs, and the HPA database verified the protein expression of the NPC2 gene. Cholesterol metabolism-related features are a promising biomarker for predicting THCA prognosis and can potentially guide personalized immunization and targeted therapy. Show less
📄 PDF DOI: 10.1007/s12672-025-03483-2
FADS1
Liangming Kang, Guihua Wu, Pengfei Lin +2 more · 2025 · Frontiers in nutrition · Frontiers · added 2026-04-24
Osteoarthritis (OA) is a multifactorial disease influenced by both genetic and environmental factors. Recent studies suggest that genetic variants involved in nutrient metabolism may interact with die Show more
Osteoarthritis (OA) is a multifactorial disease influenced by both genetic and environmental factors. Recent studies suggest that genetic variants involved in nutrient metabolism may interact with dietary factors to modulate OA risk. Understanding these gene-nutrient interactions could inform personalized prevention strategies for OA. We conducted a cross-sectional study involving 500 participants to explore associations between specific genetic variants and OA susceptibility, considering dietary intake. Genotyping focused on polymorphisms in the FADS1 gene (rs174537) related to omega-3 fatty acid metabolism, the VDR gene (rs2228570) involved in vitamin D metabolism, and the IL-6 gene (rs1800795), a marker of inflammation. Dietary intake of omega-3 fatty acids, vitamin D, and antioxidants was assessed using validated food frequency questionnaires. Gene-nutrient interactions were evaluated using multivariable logistic regression models, adjusting for potential confounders. Individuals carrying the G allele of FADS1 who reported low omega-3 fatty acid intake exhibited a significantly increased risk of OA [Odds Ratio (OR) = 1.45; 95% Confidence Interval (CI): 1.10-1.90; Show less
📄 PDF DOI: 10.3389/fnut.2025.1592974
FADS1
Jiaqi Wei, Zhen Yang, Xiaojin Wu +2 more · 2025 · Thrombosis journal · BioMed Central · added 2026-04-24
Coagulation defects, including purpura and other haemorrhagic conditions, are a critical area of medical research because of their significant health effects worldwide. Understanding the metabolic bas Show more
Coagulation defects, including purpura and other haemorrhagic conditions, are a critical area of medical research because of their significant health effects worldwide. Understanding the metabolic basis of these conditions may improve therapeutic strategies. A two-sample Mendelian randomization (MR) approach was employed to evaluate the causal relationships between the levels of 1,400 metabolites and coagulation defects. Colocalization analysis confirmed significant shared genetic influences. Pathway and protein‒protein interaction (PPI) analyses identified rate-limiting enzymes and drug targets. The impacts of lifestyle factors on metabolite levels were also explored through MR. MR analysis revealed four metabolites whose abundance was significantly associated with coagulation defects: docosapentaenoate n3 DPA 22:5n3 (DPA) (OR: 1.594, 95% CI: 1.263-2.011, P < 0.001), 1-palmitoyl-2-stearoyl-gpc (PSPC) (16:0/18:0) (OR: 1.294, 95% CI: 1.134-1.477, P < 0.001), 1-stearoyl-2-docosahexaenoyl-gpc (SDPC) (18:0/22:6) (OR: 1.232, 95% CI: 1.101-1.380, P < 0.001) and hydroxypalmitoyl sphingomyelin (HPSM) (d18:1/16:0 (OH)) (OR: 0.803, 95% CI: 0.719-0.896, P < 0.001). Colocalization analysis provided robust evidence for shared genetic loci. Pathway analysis highlighted the importance of lipid metabolism, identifying key enzymes such as FADS1, FADS2 and TCP1. PPI analysis revealed an interaction between TCP1 and plasminogen, indicating potential therapeutic synergy. Further analysis revealed that lifestyle factors, including dried fruit and oily fish intake, were linked to the abundance of metabolites associated with coagulation risk. This study identifies specific metabolites and metabolic pathways involved in coagulation defects, proposes novel therapeutic targets and highlights the roles of dietary and lifestyle interventions in the management of these conditions. These findings pave the way for personalized strategies to manage coagulation-related conditions. Show less
📄 PDF DOI: 10.1186/s12959-025-00731-x
FADS1
Sheng Dou, Yi Wei, Zongyun Lin +7 more · 2025 · Functional & integrative genomics · Springer · added 2026-04-24
Endometriosis is caused by the migration of endometrial cells to locations outside the uterine lining. Despite the increasing prevalence of endometriosis, there has been limited research on genetic ef Show more
Endometriosis is caused by the migration of endometrial cells to locations outside the uterine lining. Despite the increasing prevalence of endometriosis, there has been limited research on genetic effects, and its molecular mechanisms remain unclear. This study aimed to investigate the mechanisms underlying the development of endometriosis and to identify new genetic targets for endometriosis by integrating data from gene chips, single-cell mapping, and genome-wide association study databases. Using the Gene Expression Omnibus database, we downloaded data on normal endometrium, eutopic endometrium, and ectopic lesion tissues to explore the differentially expressed genes (DEGs) between normal and eutopic endometrium, and between eutopic and ectopic endometrium. Assessment of the relationships between DEGs and endometriosis involved differential expression, expression quantitative trait loci (eQTL), and Mendelian randomization (MR) analyses. Two single-cell atlas datasets were then analyzed to explore the mechanisms underlying disease development and progression. Intersection of MR results with DEGs between normal and eutopic endometrium highlighted 28 candidate biomarker genes (17 upregulated and 11 downregulated). Similarly, we identified two additional candidate biomarker genes by intersecting the DEGs between eutopic and ectopic endometrium with MR results. Among these 30 candidates, further filtering using single-cell datasets revealed that the histamine N-methyltransferase (HNMT), coiled-coil domain containing 28 A (CCDC28A), fatty acid desaturase 1 (FADS1) and mahogunin ring finger 1 (MGRN1) genes were differentially expressed between the normal and eutopic groups, consistent with transcriptomic and MR results. Our findings suggested that eutopic endometrium exhibits epithelial-mesenchymal transition (EMT). Cell communication analysis focused on ciliated epithelial cells expressing CDH1 and KRT23 revealed that, in the eutopic endometrium, ciliated epithelial cells are strongly correlated and interact with natural killer cells, T cells, and B cells. We identified four novel biomarker genes and found evidence for EMT in the eutopic endometrium. The mechanism of endometriosis progression may be closely related to EMT and changes in the immune microenvironment triggered by damage to ciliated epithelial cells. Show less
📄 PDF DOI: 10.1007/s10142-025-01543-y
FADS1
Li Zhang, Yadong Li, Yunjing Pu +3 more · 2025 · European journal of nutrition · Springer · added 2026-04-24
This study aims to comprehensively analyze the intricate relationship between unsaturated fatty acids (UFAs, particularly omega-3 and omega-6 UFAs) and acne, from their clinical therapeutic effects to Show more
This study aims to comprehensively analyze the intricate relationship between unsaturated fatty acids (UFAs, particularly omega-3 and omega-6 UFAs) and acne, from their clinical therapeutic effects to their underlying genetic regulatory mechanisms, to elucidate the role of UFAs in acne pathogenesis. Clinical evidence synthesis: we systematically reviewed randomized controlled trials (RCTs) to evaluate the impact of UFA supplementation on acne treatment outcomes. Genetic analysis: two-sample Mendelian randomization (MR) analysis we used to investigate causal relationships between serum UFA metabolites and acne, identifying potential key regulatory enzymes. The synthesis of these RCT studies confirmed that UFA supplementation improved acne conditions. MR analysis revealed causal links between three serum UFA metabolites and acne, with dihomo-gamma-linolenic acid (DGLA) (OR = 8.457; 95% CI: 2.367-30.214; P-value = 0.001) as a risk factor and arachidonic acid (AA) (OR = 0.209; 95% CI: 0.071-0.618; P-value = 0.005) and eicosapentaenoic acid (EPA) (OR = 0.318; 95% CI: 0.102-0.991; P-value = 0.048) as protective factors. Functional annotation suggested enzymes such as Δ5 desaturase (FADS1) and Δ6 desaturase (FADS2) may play a role in acne regulation. This study offers evidence that supports a connection between UFAs and acne, examining this relationship from both clinical and genetic angles. These findings highlight the role of specific UFAs and their associated metabolic enzymes in the development of acne. Omega-3 UFAs seem to have a protective effect against acne, whereas certain types and ratios of omega-6 UFAs might contribute to acne formation. The varied impacts of UFAs on acne could be attributed to disease processes mediated by specific enzymes. However, the study's limitations include its genetic analysis being primarily based on European populations, which limits the applicability of the findings to other groups. Future research should aim to include a more diverse range of participants to improve the generalizability of the results. Show less
📄 PDF DOI: 10.1007/s00394-025-03647-4
FADS1
Yi-Jia Huang, Yan-Ling Xie, Peng-Ying Mo +3 more · 2025 · Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica · added 2026-04-24
Based on the "gut-brain" axis, this study investigated the molecular mechanism of the antidepressant effect of Bupleuri Radix. The effect of Bupleuri Radix on human intestinal flora cultured Show more
Based on the "gut-brain" axis, this study investigated the molecular mechanism of the antidepressant effect of Bupleuri Radix. The effect of Bupleuri Radix on human intestinal flora cultured in vitro was analyzed by 16S rRNA sequencing. Differential bacteria were identified by real-time quantitative PCR(qPCR). Short-chain fatty acid(SCFA) content was determined by the GC-FID method. A depression-like mouse model was established using the "triple-one" compound stress method. Mice were administered the aqueous extract of Bupleuri Radix by gavage, transplanted with Bacteroides acidifaciens or spore-forming bacteria, or gavaged with SCFAs. Behavioral changes were assessed. SCFA content in feces was measured by GC-FID. Hippocampal(fibroblast growth factor 21, FGF21) protein expression was detected by Western blot. The formation of fibroblast growth factor receptor 1-5-hydroxytryptamine receptor 1A(FGFR1-5-HT₍₁A)R) heterodimers was examined using the Duolink PLA method. The results showed that Bupleuri Radix significantly increased the abundance of the three spore-forming bacterial genera Ruminococcus, Dorea, and Blautia(P<0.05), as well as B. acidifaciens(P<0.001). Administration of Bupleuri Radix(P<0.001 or P<0.05) and transplantation of B. acidifaciens(P<0.01) both increased the levels of SCFAs such as acetic acid and butyric acid in bacterial metabolites. Treatment with Bupleuri Radix, transplantation of B. acidifaciens, or high doses of SCFAs significantly improved depression-like behaviors in mice, increased hippocampal FGF21 expression(P<0.05, P<0.01, or P<0.001), and promoted FGFR1-5-HT₍₁A)R heterodimer formation(P<0.05 or P<0.01), whereas transplantation of spore-forming bacteria showed no obvious antidepressant effect. In conclusion, the antidepressant effect of Bupleuri Radix is mediated by intestinal bacteria such as B. acidifaciens, which regulate the synthesis and metabolism of SCFAs, thereby modulating hippocampal FGF21 expression and activating FGFR1-5-HT₍₁A)R heterodimers. Show less
no PDF DOI: 10.19540/j.cnki.cjcmm.20250825.801
FGFR1
T J Hou, M Y Wang, H X Peng +7 more · 2025 · Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · added 2026-04-24
no PDF DOI: 10.3760/cma.j.cn112338-20250509-00304
FGFR1
Man Wu, Lin Huang, Yibin Yao +4 more · 2025 · Annals of hematology · Springer · added 2026-04-24
8p11 myeloproliferative syndrome (EMS) is a rare aggressive hematologic malignancy with a poor prognosis that can rapidly develop into acute leukemia. It is characterized by the translocation of fibro Show more
8p11 myeloproliferative syndrome (EMS) is a rare aggressive hematologic malignancy with a poor prognosis that can rapidly develop into acute leukemia. It is characterized by the translocation of fibroblast growth factor receptor-1 (FGFR1), and there is still a lack of effective and reliable treatment methods at present. This report provides a new therapeutic strategy for EMS patients diagnosed with BCR-FGFR1 fusion. This report describes a case of EMS patient with a positive BCR-FGFR1 fusion gene, whose manifestations are similar to those of chronic myeloid leukemia (CML). After diagnosis by fluorescence in situ hybridization (FISH) and RNA sequencing (RNA-seq), olverembatinib, the third-generation tyrosinase inhibitor (TKI) developed in China, was used for treatment. After monotherapy and follow-up for more than one year, partial molecular response (PR) was achieved. During this period, hematologic remission and cytogenetic remission were achieved. The treatment safety of the entire process was excellent. In summary, olverembatinib provides more treatment options for rare diseases such as 8p11 myeloproliferative syndrome. Show less
📄 PDF DOI: 10.1007/s00277-025-06522-8
FGFR1
Haixiong Tang, Lin Fu, Changyun Yang +9 more · 2025 · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · added 2026-04-24
Cadherin-11 (CDH11), a specialized cell-cell adhesion protein, plays an essential role in tissue injury, inflammation and repair. This study aimed to investigate the role of CDH11 in severe asthma. Br Show more
Cadherin-11 (CDH11), a specialized cell-cell adhesion protein, plays an essential role in tissue injury, inflammation and repair. This study aimed to investigate the role of CDH11 in severe asthma. Bronchial biopsy specimens were obtained from healthy subjects and patients with severe asthma. Two murine models of severe asthma were established using either TDI (toluene diisocyanate) or OVA (ovalbumin)/CFA (complete Freund's adjuvants). A selective CDH11 antagonist SD133 (100 mg/kg) was given to allergen-exposed mice after airway challenge. The effects of recombinant CDH11 were also tested in vivo, and FGFR1 inhibition was used to explore a possible mechanism for CDH11-induced inflammatory responses in the lung. We detected upregulated expression of CDH11 in the airway mucosa of severe asthma patients when compared with the healthy control. In the OVA/CFA-induced model, though CDH11 expression in the lung remained unchanged, pharmacological antagonism of CDH11 with SD133 dramatically decreased airway neutrophil accumulation, as well as IL-6 production, but had no effect on eosinophilic infiltration, type 2 inflammation (IL-4 and IL-5) nor airway hyperresponsiveness. In the TDI model, pulmonary CDH11 expression was upregulated. Treatment with SD133 inhibited TDI-induced airway hyperresponsiveness and neutrophilic inflammation, decreased IL-6 and TNF-α production, with no effect on airway eosinophil counts and type 2 inflammatory cytokines. In addition, intratracheal instillation of recombinant CDH11 led to neutrophil recruitment in the lungs of mice, which could be attenuated by inhibition of FGFR1 signaling. CDH11 contributes to airway neutrophilic inflammation in severe asthma through the FGFR1 pathway. Show less
no PDF DOI: 10.1096/fj.202501899RR
FGFR1
Dongxia Fu, Yongxing Chen, Xue Wu +3 more · 2025 · BMC pediatrics · BioMed Central · added 2026-04-24
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by deficient secretion or action of gonadotropin-releasing hormone. While its characteristics are well-documented in adults, da Show more
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder caused by deficient secretion or action of gonadotropin-releasing hormone. While its characteristics are well-documented in adults, data from prepubertal patients remain limited. To investigate the clinical, hormonal, and genetic characteristics of CHH in male patients aged < 18 years and assess age-related changes in testicular function. Retrospective analysis of data from patients with CHH. Tertiary pediatric endocrine referral center. Overall, 121 male patients with CHH, aged 0-18 years, were included. Hormonal profiles, genetic variants, and testicular function indicators across different age groups. All patients had micropenis, and 41.3% had cryptorchidism. The > 14-year group had fewer combined cases of both conditions but more isolated micropenis (p = 0.001). Inhibin B, luteinizing hormone, follicle-stimulating hormone, and post-human chorionic gonadotropin testosterone levels were significantly higher in the ≤ 3-year group (p < 0.05). Leydig and Sertoli cell function declined with age. Inhibin B < 33.895 pg/mL and anti-Müllerian hormone (AMH) < 17.545 ng/mL predicted Leydig cell dysfunction with sensitivities of 78.5% and 85.7% and specificities of 82.3% and 73.8%, respectively. Pathogenic variants were identified in 84.6% of cases, with fibroblast growth factor receptor 1, chromodomain helicase DNA-binding protein 7, and prokineticin receptor 2 being the most frequently impacted. CHH should be suspected in boys with micropenis and cryptorchidism. AMH and inhibin B are key markers for early detection of Leydig cell dysfunction, with genetic testing being essential for diagnosis. Show less
📄 PDF DOI: 10.1186/s12887-025-06162-x
FGFR1
Riya Keshri, Marc Exposit, Mohamad Abedi +22 more · 2025 · bioRxiv : the preprint server for biology · Cold Spring Harbor Laboratory · added 2026-04-24
Growth factor induced receptor dimerization and activation of downstream pathways can modulate cell fate decisions. Here, we investigate the potential of de novo designed synthetic ligands, termed Nov Show more
Growth factor induced receptor dimerization and activation of downstream pathways can modulate cell fate decisions. Here, we investigate the potential of de novo designed synthetic ligands, termed Novokines, to reprogram cell identity by inducing proximity of novel pairs of receptor subunits. We find that a design, H2F, that brings together HER2 (which has no known natural ligand) and the FGF receptor has potent signaling activity. H2F induces robust signaling and reprograms fibroblasts into myogenic cells. Unlike native FGF ligands, H2F selectively activates the MAPK pathway without engaging PLCγ-mediated Ca²⁺ signaling. FRET assays confirm H2F-mediated HER2-FGFR proximity, and phosphoproteomic analysis reveals activation of MAPK effectors. H2F-induced ERK phosphorylation is abolished in cells expressing a kinase-dead FGFR1 (K514M) mutant, confirming the requirement for FGFR catalytic activity. H2F treatment significantly increases myofiber formation from adult patient-derived primary myoblasts, demonstrating its capacity to promote myogenic regeneration. Our findings demonstrate that synthetic receptor pairings can rewire signaling outputs to drive regeneration, providing a programmable platform for cell fate engineering. Show less
no PDF DOI: 10.1101/2025.10.12.681903
FGFR1
Yiqiao Deng, Chengyao Guo, Xiaomeng Liu +14 more · 2025 · Experimental & molecular medicine · Nature · added 2026-04-24
Tumor fibrosis is recognized as a malignant hallmark in various solid tumors; however, the clinical importance and associated molecular characteristics of tumor fibrosis in liver metastases (LM) from Show more
Tumor fibrosis is recognized as a malignant hallmark in various solid tumors; however, the clinical importance and associated molecular characteristics of tumor fibrosis in liver metastases (LM) from colorectal cancer (CRLM) remain poorly understood. Here we show that patients with CRLM whose liver metastases (LM) exhibited tumor fibrosis (Fibrosis+ LM) had significantly worse progression-free survival (P = 0.025) and overall survival (P = 0.008). Single-cell RNA sequencing revealed that the tumor microenvironment of the Fibrosis+ LM was characterized by T cells with an exhausted phenotype, macrophages displaying a profibrotic and suppressive phenotype and fibrosis-promoting fibroblasts. Further investigation highlighted the pivotal role of VCAN_eCAF in remodeling the tumor fibrosis in the tumor microenvironment of Fibrosis+ LM, emphasizing potential targetable interactions such as FGF23 or FGF3-FGFR1. Validation through multiplex immunohistochemistry/immunofluorescence and spatial transcriptomics supported these findings. Here we present a comprehensive single-cell atlas of tumor fibrosis in LM, revealing the intricate multicellular environment and molecular features associated with it. These insights deepen our understanding of tumor fibrosis mechanisms and inform improved clinical diagnosis and treatment strategies. Show less
📄 PDF DOI: 10.1038/s12276-025-01573-3
FGFR1
X L Su, J W Wu, P L Wang +7 more · 2025 · Zhonghua bing li xue za zhi = Chinese journal of pathology · added 2026-04-24
no PDF DOI: 10.3760/cma.j.cn112151-20250517-00349
FGFR1
Miao Sun, Yan Liu, Maolin Liu +5 more · 2025 · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · Taylor & Francis · added 2026-04-24
Congenital hypogonadotropic hypogonadism (CHH) is a rare condition characterized by incomplete pubertal development, infertility, and gonadotropin-releasing hormone deficiency, associated with mutatio Show more
Congenital hypogonadotropic hypogonadism (CHH) is a rare condition characterized by incomplete pubertal development, infertility, and gonadotropin-releasing hormone deficiency, associated with mutations in more than 50 genes. We aimed to conduct an etiological analysis of a CHH Chinese family and summarize the clinical presentations and genetic changes of reported similar cases. Whole-exome sequencing (WES) was performed to identify the molecular cause in the proband. In silico tools were employed to analyze the pathogenicity of the variants. Reported cases with similar clinical features and associated genes were summarized by searching through PubMed/MEDLINE using keywords 'FGFR1,' 'CHH,' and 'Kallmann syndrome (KS).' Genetic analysis revealed a novel likely pathogenic deletion mutation in the FGFR1 gene (NM₀₂₃₁₁₀.3: c.263₂₆₄del (Val88Alafs*22)) in a Chinese family exhibiting micropenis and underdeveloped testes. A total of 38 cases with CHH or KS have been previously reported. This study identified a novel FGFR1 deletion variant responsible for CHH, expanding the known mutational spectrum of FGFR1. Typical manifestations include delayed puberty and diverse presentations. The genotype-phenotype correlation in CHH remains unclear and may involve oligogenic effects and epigenetic regulation. Show less
no PDF DOI: 10.1080/09513590.2025.2571656
FGFR1
Yufeng Qiao, Zhenzhen Wu, Peng Wang +18 more · 2025 · The Journal of clinical investigation · added 2026-04-24
Protein arginine methyltransferase 5 (PRMT5) complexes with methylosome protein 50 (MEP50) play crucial roles in tumor progress. However, the regulatory mechanism of governing the PRMT5-MEP50 hetero-o Show more
Protein arginine methyltransferase 5 (PRMT5) complexes with methylosome protein 50 (MEP50) play crucial roles in tumor progress. However, the regulatory mechanism of governing the PRMT5-MEP50 hetero-octameric complex remains unclear. Here, we demonstrate that C6orf223, to our knowledge an uncharacterized protein, facilitates PRMT5-MEP50 multiprotein complex assembling, thereby promoting colorectal cancer (CRC) growth and metastasis. C6orf223 forms dimers through disulfide bonds, with its N-terminal arginine-enriched region binding to the C-terminal negatively charged groove of PRMT5, thus stabilizing PRMT5-MEP50 multiprotein and enhancing PRMT5 methyltransferase activity. Consequently, PRMT5-mediated H4R3me2s substantially decreases the expression of the tumor suppressor GATA5, leading to the upregulation of multiple oncogenic target genes including WWTR1, FGFR1, and CLU. Targeting C6orf223 using siRNAs encapsulated in ferritin protein shells effectively suppresses CRC tumor growth and metastasis. Collectively, our findings characterize the role of C6orf223 in facilitating PRMT5-MEP50 hetero-octameric complex assembling and suggest that C6orf223 could serve as a potential therapeutic target for CRC. Show less
📄 PDF DOI: 10.1172/JCI186052
FGFR1
X Lyu, R Cai, B Han +10 more · 2025 · ESMO open · Elsevier · added 2026-04-24
Fibroblast growth factor receptor (FGFR) alterations are established therapeutic targets in cholangiocarcinoma and urothelial carcinoma but remain understudied in colorectal cancer (CRC). This study i Show more
Fibroblast growth factor receptor (FGFR) alterations are established therapeutic targets in cholangiocarcinoma and urothelial carcinoma but remain understudied in colorectal cancer (CRC). This study investigates the prevalence, clinicopathological correlates, and prognostic impact of FGFR alterations in CRC. We analyzed 608 stage I-IV CRC samples (2014-2024) through next-generation sequencing (NGS) and immunohistochemistry (IHC). FGFR genomic status was correlated with survival outcomes using Kaplan-Meier and Cox regression analyses. External validation of FGFR genomic alterations was carried out using the 19 datasets (n = 6998) with prognostic impact validated through The Cancer Genome Atlas Colon and Rectum Adenocarcinoma (COREAD) dataset (Firehose Legacy, n = 640), both accessed via cBioPortal database. Large-scale genomic profiling of CRC [n = 7606 (608 in-house + 6998 public cohorts)] identified FGFR1 amplification (3.8% prevalence) as the predominant FGFR alteration subtype. Multivariable analysis confirmed FGFR alterations as independent predictors of poor disease-free survival [DFS; hazard ratio (HR) 2.58, P = 0.0002] and progression-free survival (PFS; HR 2.17, P = 0.0011), with FGFR1 amplification showing strongest prognostic impact (DFS HR 2.91, PFS HR 2.52, P < 0.01). Notably, the prognostic magnitude of FGFR alterations was comparable to KRAS/BRAF mutations in both localized and metastatic CRC. In addition, we established a semiquantitative immunoreactive score (IRS) system achieving 95.2% concordance with NGS (κ = 0.901), enabling reliable FGFR1 screening in routine pathology workflows. This study provides the first comprehensive characterization of FGFR genomic alterations in CRC through large-scale profiling (n = 7606), establishing FGFR1 amplification as the predominant alteration. Unlike FGFR2/3-driven malignancies, FGFR1-amplified CRC exhibited aggressive clinical behavior and inferior survival outcomes across disease stages. To address the diagnostic challenges in routine practice, we further developed a validated immunohistochemical scoring system (IRS), establishing a cost-effective and clinically feasible alternative to molecular assays for identifying FGFR1-driven CRC subsets. Show less
📄 PDF DOI: 10.1016/j.esmoop.2025.105561
FGFR1
Kaihao Wang, Yipeng Du, Peixin Li +5 more · 2025 · Materials today. Bio · Elsevier · added 2026-04-24
Ischemia-reperfusion (IR) and adriamycin (also named doxorubicin, DOX)-induced acute myocardial injuries have a significant impact on health, causing serious economic and medical burdens. Therefore, w Show more
Ischemia-reperfusion (IR) and adriamycin (also named doxorubicin, DOX)-induced acute myocardial injuries have a significant impact on health, causing serious economic and medical burdens. Therefore, we need to explore and identify drugs with potential therapeutic value for treating I/R- and DOX-induced myocardial injury. In the present study, we explored the therapeutic potential of FGF4 for I/R and DOX-induced myocardial injury. We found that FGF4 showed good improvement in acute cardiac injury. However, due to the short half-life of FGF4, we further prepared a myocardial-targeted FGF4-sustained release nanoliposome (named FGF4-NANO-IMTP). We investigated the effect of FGF4-NANO-IMTP on myocardial injury caused by I/R and DOX. Show less
📄 PDF DOI: 10.1016/j.mtbio.2025.101984
FGFR1
Yushun Wu, Jing Liu, Wenying Yu +3 more · 2025 · Frontiers in immunology · Frontiers · added 2026-04-24
Knee osteoarthritis (KOA) is a chronic inflammatory joint disorder marked by cartilage degradation and immune microenvironment dysregulation. While transcriptomic studies have identified key pathways Show more
Knee osteoarthritis (KOA) is a chronic inflammatory joint disorder marked by cartilage degradation and immune microenvironment dysregulation. While transcriptomic studies have identified key pathways in KOA, the interplay between ferroptosis (an iron-dependent cell death mechanism) and immune dysfunction at single-cell resolution remains unexplored. This study integrates single-cell and bulk transcriptomics to dissect ferroptosis-driven immune remodeling and identify diagnostic biomarkers in KOA. We analyzed scRNA-seq data (GSE255460, Twelve chondrocyte clusters were identified, including ferroptosis-active homeostasis chondrocytes (HomC) ( This study establishes ferroptosis as one of the key drivers immune-metabolic dysfunction in KOA, with HomC acting as a hub for FGF-mediated synovitis and ECM remodeling. The diagnostic model and regulon network ( Show less
📄 PDF DOI: 10.3389/fimmu.2025.1608378
FGFR1
Haonan Guo, Yingyu Jing, Yifan Zhang +11 more · 2025 · Obesity (Silver Spring, Md.) · Wiley · added 2026-04-24
Obesity in women of childbearing age disrupts lipid metabolism in pregnancy. This study aims to evaluate the impact of prepregnancy glucagon-like peptide-1 receptor agonist (GLP-1RA) use on lipid meta Show more
Obesity in women of childbearing age disrupts lipid metabolism in pregnancy. This study aims to evaluate the impact of prepregnancy glucagon-like peptide-1 receptor agonist (GLP-1RA) use on lipid metabolism during pregnancy. A retrospective case-control study with 42 participants was employed to analyze the impact of prepregnancy GLP-1RA use on lipid metabolism during pregnancy in women with obesity. An animal study involved 60 virgin female Sprague Dawley rats fed a normal diet or a high-fat diet (HFD) for 8 weeks, with the latter diet divided into HFD + saline, HFD + liraglutide, and HFD + semaglutide for 4 weeks. Rats were mated and then sacrificed on gestational day 21. Clinically, prepregnancy GLP-1RA use reduced prepregnancy BMI, gestational weight gain, ratio with first-trimester metabolic dysfunction-associated steatotic liver disease, and triglyceride levels during pregnancy. In animals, GLP-1RA improved plasma fibroblast growth factor 21 (FGF21), adiponectin, triglyceride levels, and leptin in midgestation. During late gestation, compared with the HFD group, the GLP-1RA groups exhibited improved liver lipid deposition, increased fatty acid oxidation and lipolysis genes, decreased lipogenesis genes, and increased extracellular signal-regulated kinase (ERK)/peroxisome proliferator-activated receptor γ (PPAR-γ) and AMP-activated protein kinase (AMPK)/NAD-dependent protein deacetylase sirtuin-1 (SIRT1) pathways in liver; in the visceral adipose, the GLP-1RA groups showed increased lipolysis genes, decreased lipogenesis genes, and increased phosphorylated to total fibroblast growth factor receptor 1 (FGFR1) with activated ERK/PPAR-γ pathways. Prepregnancy GLP-1RA use improves maternal lipid metabolism during pregnancy, potentially involving elevated liver-secreted FGF21. This study offers a new strategy for treating lipid metabolic disorders in pregnancy. Show less
no PDF DOI: 10.1002/oby.24328
FGFR1
Xue Chen, Lili Yuan, Xiaoli Ma +8 more · 2025 · Annals of hematology · Springer · added 2026-04-24
Myeloid/lymphoid neoplasms with tyrosine kinase gene fusions (MLN-TK) are rare hematologic malignancies characterized by recurrent kinase rearrangements, including
📄 PDF DOI: 10.1007/s00277-025-06494-9
FGFR1